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Global Vaccines and Immunology

Review Article

Vaccines and the looming threat of syphilis
Charles T. Ambrose*

Department of Microbiology, Immunology, and Molecular Genetics, College of Medicine, University of Kentucky, USA

Abstract
During the past several decades, syphilis has increased in the US and explosively so in China and Russia. While most current cases can be cured by penicillin or
second line antibiotics, strains of the syphilis spirochete (Treponema pallidum) resistant to the latter have emerged. And the potential of strains to acquire resistance
to penicillin via plasmids has recently been recognized. The 36 million-plus undertreated cases of syphilis in the world represent metaphorically a vast global 37°C
incubator allowing exchange of antibiotic resistant genes among the human-borne bacteria and theoretically permitting the emergence of penicillin resistant strains.
None has yet been identified but they seem inevitable along with the threat of multi-resistant strains.
There is now concern over the lack of new antibiotics to succeed the penicillins. Since such new drugs would likely require a decade or so of research and federal
approval, vaccine-based protection is of immediate consideration here. This approach may exploit the new knowledge about the biology of T. pallidum strains their
many complex antigens, serotypes, and the latter’s distribution in populations. Equally important are recent insights into immunology, such as cellular aspects and
antigenic competition.

Introduction
While the prevalence of syphilis in the United States has nearly
tripled over the past decade or so, this disease may present an even
greater threat to public health in the future [1]. During the past two
decades in China there has been 30-fold increase in syphilis and in
Russia nearly a 70-fold increase. If this ‘explosive resurgence’ abroad
continues and spreads throughout the world, in time it might lead
to the emergence of strains of the syphilis spirochete (Treponema
pallidum) resistant to penicillin, which has been the standard therapy
for the infection since the 1940s. Such deadly strains would eventually
reach this country. Resistance to antibiotics (including to penicillin)
is present in many bacteria and is transferred among them by genetic
means discussed later. Conditions for the appearance of resistant
strains of syphilis to penicillin and other ‘back-up’ antibiotics are
especially optimal globally with so many millions of untreated persons
harboring multi-drug resistant bacteria. Clinicians are worried about
the current absence of new antibiotics to treat many newly resistant
human pathogens [2].
This essay reviews briefly the global increase of venereal syphilis
and discusses the genetic basis of potential penicillin resistance in T.
pallidum (Sections 2 & 3). During the mid-19th century, vaccines were
sought for syphilis unsuccessfully, but a century later they seemed
unnecessary with the advent of effective antibiotics. However, today
with the theoretical threat of antibiotic-resistant syphilis emerging and
in the current absence of new successor antibiotics, there is revived
interest in vaccines for syphilis.
Treponemal pallidum causes venereal syphilis. Milder, nonvenereal, cutaneous infections are produced by other closely related
treponemal species/strains, such as yaws, pinta, and bejel (Sec. 4). The
genetic relationship among these five pathogens is treated here. New
information about treponemal surface antigens is reviewed next (Sec.
5). Genetic typing of T. pallidum has revealed that multiple strains are
prevalent in a human community at any one time. These may compete
with one another during a given luetic infection (Sec. 6 & 8). How to
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exploit this newer knowledge in devising a vaccine is the challenge at
hand.

The recent resurgence of syphilis (Lues venerea)
In the US before the Second World War, syphilis was estimated
to have infected 5% to 10% of the US general population and 25% of
impoverished groups especially those in southern states. In 1937, US
Surgeon General Thomas Parran (1892-1968) had called syphilis the
“shadow on the land” [3]. In 1947 the overall prevalence was 66/100,000
but declined dramatically after penicillin became available in the mid1940s to the level of 2.1/100,000 by 2000 [4]. However, during the so
called ‘sexual revolution’ it rose to 5.5/100,000 by 2013 with 9.3/100,000
in men [1]. A striking example of this increase was the epidemic in San
Francisco, where the prevalence was 3.8/100,000 in 1999 and rose to
26/100,000 in 2007 [5] (Table 1).
In China the disease was reported to have been largely eradicated
(<2/100,000) in the 1960s by aggressive public health policies of the
government. But in recent years there has been an “explosive return
of the Great Pox” a 25-fold increase from the early 1990s to 2007
and a further 5-fold increase through 2011 [6-8]. The incidence rose
to 8.71/100,000 in 2005 throughout the country and to 32/100,000 in
2011. It was much higher in many cities e.g., 77/100,000 in Shanghai
in 2008 [9]. The one-child policy of the Communist government and
female-weighted abortions in families led to an excess of unmarried
males and accounted for the rise in MSM (male-sex-male) venereal
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Table 1. Global Prevalence of Syphilis per 100,000 Population.
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infections [7]. Migration into crowded cities promoted spread of the
disease (Table 1).
In Russia, the collapse of its health system during the 1990s has led
a similar rise in syphilis and other infectious diseases for syphilis from
4/100,000 in 1988 to 263/100,000 in 1996 [10]. In St. Petersburg the
prevalence was 318/100,000 in 1995 [11] (Table 1).
Throughout the world, according to recent estimates, syphilis
infects 36 million persons and is newly acquired each year by 11
million more. It causes over 100,000 deaths in spite of penicillin being
considered an effective cure for nearly all current luetic infections [1214] (Table 1).

Penicillin and T. pallidum
Since the mid- 1940s, the standard therapy for syphilis has involved
various forms of penicillin agents containing a critical β-lactam ring.
Syphilitics allergic to penicillin have been treated with second-line
antibiotics e.g., macrolides (azithromycin, erythromycin, spiramycin)
and tetracyclines (doxycycline, etc.) [15]. However, strains of T.
pallidum resistant to these second-line antibiotics have appeared an
example being azithromycin resistance, which was found in 77.3% of
the T. pallidum specimens isolated in 2006 in San Francisco [5].
To date, no penicillin-resistant strains of T. pallidum have been
reported, but they seem inevitable. The 36 million-plus people infected
with T. pallidum represent a global microbial pool capable of spreading
the syphilis among their billion neighbors. Each person (infected or
not) is a 37°C incubator harboring in the GI tract and elsewhere a
vast array of bacteria which interact with one another notably in
transferring genetic information via plasmids. These are small pieces
of DNA containing genes, including some coding antibiotic resistance.
For example, strains of Neisseria gonorrhoeae acquired resistance
to penicillin and its derivatives via plasmids encoding β-lactamase
activity which came from ampicillin-resistant strains of Haemophilus
influenzae [16]. The enzyme β-lactamase, inactivates penicillin by
disabling its essential β-lactam ring.
Surprising and disturbing to siphilologists was the discovery in
1981 that plasmids exist in T. pallidum, thus indicating that it has the
potential to acquire resistance to penicillin by genetic mechanisms
frequently used by other bacteria [17,18]. One such example is a strain
of Klebsiella pneumoniae (an enteric organism) containing an enzyme
which breaks down carbapenem (a β-lactam antibiotic like penicillin
G). The gene for this enzyme is contained in a plasmid, which can
move from K. pneumoniae to other bacteria (e.g., T. pallidum). This
condition represents “a risk as serious as terrorism” [19].
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The ultimate therapeutic threat would be strains of T. pallidum
exhibiting resistance to all forms of penicillin and also to backup
antibiotics. The medical literature is filled with other examples
of multiple drug resistance i.e., in staphylococci, enteric bacilli,
Mycobacterium tuberculosis, etc. [20]. The World Health Organization
and other public health agencies have declared antibiotic resistance to
be the greatest threat to global public health [21]. A multiple resistant
strain of T. pallidum seems likely to appear somewhere and enter the US
population, facilitated by the international travel of infected persons.
A growing concern here is that the “developmental pipeline
(for new antibiotic agents) is empty” because many drug companies
have found this area unprofitable, focusing instead on drugs treating
common chronic diseases. Roche “fled the field in 1999.” Eli Lilly
“dropped its antibiotic research in 2002,” and other companies joined
them in abandoning the area [22]. The continued emergence of drugresistant bacteria has prompted the US government “to coax companies
back to the field,” but the productive momentum they once had may
take years to regain.
While new anti-syphilitic drugs would be aggressively sought by
the pharmaceutical industry in the event of an epidemic of a resistant
strain, there is no great pressure to do so in advance of the therapeutic,
commercial demand. Meanwhile, alternate treatments need be
considered, such as vaccines. Recent discoveries in the immunology
and genetics of the treponemes, extending also to those species/
subspecies of this genus causing non-venereal diseases, may help devise
an effective vaccine.

Treponemal diseases in the world
Siphilologists have been conflicted over relationships among the
various treponemal pathogens accounting for four related diseases seen
throughout the world venereal syphilis, yaws, pinta, and bejel (endemic
syphilis). All these treponemes are morphologically identical and
closely related serologically. All currently are suppressed by penicillin
but produce different pathologies, which are summarized below. It’s
uncertain whether there is any protective cross-reaction among the
four agents, but some reciprocal immunity may exist between yaws and
syphilis as judged by the latter’s relative absence in areas with a high
prevalence of yaws [23,24].
Venereal syphilis (VS, lues venerea) elicits genital lesions (chancres)
initially and later affects various organ systems as ‘tertiary sequelae’
in around 30% of untreated cases. In contrast, three non-venereal
treponemal infections produce conspicuous lesions on the exposed
parts of the body but no significant constitutional/systemic symptoms
(i.e., no chills, fever, weight loss, etc.) and no later organ involvement.
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Yaws (Y) occurs in warm humid rural areas of Africa, SE Asia, and the
Americas and causes multiple granular papillomas on unclothed legs,
arms, and the face of children mainly. Pinta (P) is present primarily in
South/Central America and causes dry scaly lesions on exposed skin.
Bejel (B) is found in the dry, warm Middle East, and in severe cases
may produce gummatous ulcerative lesion on the face. Bejel in Europe
is also termed endemic syphilis. The latter two (P, B) are characterized
also by moist papules in the axilla and skin folds and mucous patches
in the mouth.
The characteristic clinical pictures produced by T. palllidum and
the non-venereal treponemes reflect the particular tissue tropism of
the respective infecting species/strains i.e., area of the body primarily
affected (tropism, Gr. = ‘turning’ to some area). The non-venereal
treponemes infect mainly the skin and mouth but not the warmer
internal organs of the body. For example, unlike venereal syphilis,
neither yaws, pinta, nor bejel produces neurological sequelae nor are
they transmitted from an infected mother to her foetus [23].
Strain differences may also account for the various clinical pictures
seen during late/tertiary stages of venereal syphilis i.e, gummatous
bony lesions, cardiovascular pathology, or neurological involvement.
One particular strain has been found more often in persons with
neurosyphilis than in other syphilitics, again suggesting subspecies
tropism [24,25].
Medical historians have speculated on how these subtypes evolved
and how lues venerea entered into Europe during the mid-1490s. The
Columbian theory proposes that this virulent disease arose from a
non-venereal treponeme in the Americas and was imported from the
Caribbean by infected sailors returning from Columbus’ first voyage
there. Other theories attribute decaying matter or animals in Africa as
the origin of non-venereal treponemes which subsequently infected
people and spread via them to the Americas and Europe, ultimately
producing lues venerea. Endnote #1 summarizes such speculations by
three investigators which link the various treponemal strains from an
evolutionary standpoint [28-30].
K.N. Harper et al. provided scientific support for the Columbian
theory of syphilis’ entrance into Europe from America based on
DNA analyses. This group sequenced select gene regions of twentysix geographically dispersed strains of pathogenic treponemes and
concluded that strains causing venereal syphilis now resemble
phylogenetically yaws strains from South America [31]. These studies
lead logically to a review of treponemal antigens, strain typing, and
distribution of the many T. pallidum strains.

Antigens and strain typing of T. pallidum subspp.
pallidum
Subspecies and strain differences reflect in part the complex
array of spirochetal surface antigens. Treponemes have a fragile outer
membrane and a more stable inner one. The former contains unstable
antigenic determinants coded by twelve T. pallidum repeat genes
(Tpr). Different strains express different combinations of Tpr proteins
[32]. The inner membrane contains several lipoprotein antigens (e.g.,
TpN47, TpN17, etc.), which are accessible for expression only when
the outer membrane is disrupted or aged. Adding to this complexity
is the fact that within one particular antigen (TprK) are seven discrete
variable regions coded by different alleles [33]. The relative importance
of these different antigens in producing protective immunity is unclear
at present, but progress has begun in distinguishing different strains.
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Allen Pillay and colleagues developed a method for typing strains
of T. pallidum [34]. Intrastrain variability is exhibited by two genes a
member of the T. pallidum repeat (tpr=Tpr) gene family and the acidic
repeat protein (arp) gene. The method involves isolating both genes
from a sample, amplifying them by polymerase chain reaction, and
analyzing the products of endonuclease digestion. More than 40 strain
types have been identified (e.g., 14a, 14d, 15a, etc.) and many subtypes
(12df, 14d9, etc.).
Subsequent studies using this new technique have shown that many
different strains (up to 16 or so) are present during the same period in
a given large urban areas [35]. For example, during 1999-2008, strain
type 14d9 represented 53% of the 4 different strains recovered from 69
of persons in San Francisco and 51% of the 8 found in Seattle [5,36].
Strain type 14a comprised 54% of the 4 different strains found in
Pretoria and 50% of the 3 in Lisbon [36]. Thus different sexual partners
in a community may harbor different strains. To date, so far as I am
aware, only one strain has been identified in a given individual, but
this may reflect not having examined numerous samples from the same
person and perhaps not early enough.

Luetic infections clearance vs. reduction = cure vs.
protection
Although lacking confirmation, one current supposition is that a
given syphilitic may harbor initially several strains of T. pallidum –
i.e., genetically different subpopulations, each with a wide repertoire
of antigens [37]. This diversity could come about in two ways. 1)
contacts with different sexual partners would allow the introduction of
several different strains from the different ‘spirochetal donors’. 2) New
antigenic subtypes might also arise de novo by mutations of spirochetes
present in an individual.
During the month or so after a person becomes infected from one or
more sexual partners and while the immune response is being engaged,
many or most of the acquired treponemes are assumed to be cleared,
but one or more may persist to produce clinical manifestations [38,39].
Of the several concurrent infecting strains of T. pallidum, those with
stronger or more accessible antigen may produce a ‘robust’ immune
response and be eliminated by opsonic antibodies/phagocytosis and
delayed-type immunity, while the ‘weaker’ strain/s would evoke a
lesser response, might escape immune surveillance, and thus survive
in the host to produce disease [32]. Whether immunological tolerance
might develop to this ‘survivor’ strain is a consideration. Cullen and
Cremer have made a distinction between protection from the disease
(nonsterile immunity due merely to reduced spirochetal numbers) and
complete clearance of the organism (sterile immunity) [40].
The following is a plausible ‘strain’ history for an untreated
syphilitic, but this scenario has not yet been validated by typing studies.
In a given person, an early reduction in strain varieties from immune
surveillance may be offset by new strains acquired during later sexual
contacts or possibly by mutations in stains already present. Thus the
initial repertoire of treponemal strains in that person may change over
time.

Studies on syphilis ‘vaccination’ past and recent
Philippe Ricord (1800-1889), the famous French venereologist,
advocated ‘vaccinating’ against syphilis in a long series of letters to
the Editor of the Union Médicale of Paris, 1850-51. (Endnote#2)
Syphilologists then distinguished between indurated (hardened)
and non-indurated chancres and believed that multiple inoculations
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with the “virulent pus” from the latter over many months could be a
“prophylaxis against constitutional syphilis” (tertiary sequellae) much
as vaccinia from cowpox pustules protects people from smallpox [41].
A contentious issue at that time was how many sequential contacts
with chancre fluid/pus were needed to ‘induce immunity’ up to a
score or more, some maintained. Proof of immunity for the French
investigators then seemed to be merely the later absence of signs of
secondary or tertiary syphilis.
Interest in immunizing for syphilis resumed a century later with
investigators who sought to obtain non-infectious strains by heating
isolates or using other procedures. Their negative results were likely
due to labile surface antigens being destroyed in the process. The
first limited success was obtained in 1969 by Metzer et al. In earlier
studies these investigators had established the protein nature of the
immunizing antigens and next sought to attenuate/reduce strain
virulence by storage at 4°C for 7-10 days. They used a Nichols strain
of T. pallidum to vaccinate rabbits by IV injections 4-times/week for 7
weeks [42]. Some of the rabbits showed “a high degree of immunity”
upon challenge with infectious treponemes i.e., no lesions/chancres
appeared at the inoculating sites in the skin. But spirochetes were
still latent in the treated rabbits i.e., “sterile immunity” had not been
achieved.
In later, more successful immunization studies, James N. Miller
sought to preserve labile surface antigens by using a γ-irradiated, now
non-infectious Nichols strain. He administered this preparation to
rabbits IV daily over a 37-week period and found them “completely
resistant to intradermal challenge (with homologous treponemes)
administered 10 days after the last immunizing injection” [43].
Protection persisted for one year. There was minimal immunity to
challenge with T. pertenue, the agent of yaws thus indicating specificity
for venereal syphilis.
The 37-week long injection protocol in rabbits would not be
practical in human subjects. In any case, the prospect for successful
immunization is complicated by the possibility that several strains of
T. pallidum may infect a given person at the same time. Whether each
impedes or influences the immune responses (and the elimination) of
others is an issue examined next.

Antigenic competition
Differences in the immune responses of several concurrently
infecting T. pallidum strains are likely due to the ‘strength’ of their
presenting antigens, but another influence might be that of antigenic
competition, as explained next. Immunization with two antigens
given together (or within days of each other) elicits separate immune
responses for both, but the level of each response is lower with paired
stimulation than when either antigen is given alone. In other words, two
antigen introduced together limit reciprocally somewhat the response
of each other. There is considerable variability here, depending on the
type of the antigens, the doses, the timing of each stimulus, etc. The
nature of this competition was the subject of scores of research papers
and reviews in the 1970s [44,45].
My studies in this area then involved lymph node organ cultures
prepared from rabbits primed months earlier with two antigens e.g.,
bovine serum albumin and diphtheria toxoid. Each culture consisted of
a dozen 1 mm3 size lymph node fragments bathed in 1 ml of a chemically
defined medium [46]. Incubating the cultures with the antigens on Day
0 for two hours elicited the secondary antibody responses to both,
which continued over a month as measured in the medium replaced
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every three days. Pooled lymph nodes from a single primed rabbit
provides 60-100 culture tubes, thus allowing many variables (each
in 4 or more replicate tubes) to be examined in one experiment e.g.,
detailed dose response effects. The individual responses were measured
in the culture medium by hemagglutination titration assays.
The antigenic competition demonstrated in this culture system
was not due to some limiting nutritional factor [47]. Related to this
phenomenon was the surprising observation that very low levels of
certain antibiotics enhanced antibody production in these cultures. For
example, adding increasing levels of chloramphenicol or actinomycin
D during the inductive phase of the in vitro response (Days 0-6),
produced the expected dose response inhibition during the subsequent
productive phase (Days 6-30+). However, extremely low levels of these
same agents included after Day 6 cause a paradoxical increase in the
antibody responses [46,48].
This observation led to the isolation and characterization of an
‘antibody inhibitory material’ (AIM) released in the spent medium
[48,49]. The highest inhibitory effect was found in medium recovered
on Day 6, 9, & 12 of the 18-day culture period. I postulated that the
paradoxical increase was due to AIM-containing cells producing
less AIM because of their being more sensitive to the low levels of
actinomycin D than the antibody secreting cells. Other investigators
also identified such inhibitory factors (cytokines) and termed them
‘suppressor’ factor/s i.e., products of so-called ‘suppressor’ cells (Ts). A
decade later, ‘T regulatory cells’ (Treg) became the preferred term [50].
More recently, Tregs have been hypothesized these to be of two types
one is specific for a given antigen, while another is ‘non-specific’ the
latter presumably being involved in antigenic competition [50,51].
Examining this phenomenon in terms of antibody production, allergy,
and autoimmunity has been the subject of numerous reviews during
the past several decades [50-54]. Relevant to the subject of syphilis
is whether the multiple antigens of one spirochete strain infecting a
person exert antigenic competition with other introduced strains.
A ‘classical’ immunization approach has employed a ‘mild’
live organism related to a major pathogen in order elicit protective
immunity against the latter e.g., M. bovis for M. tuberculosis and cowpox
or vaccinia virus for the variola virus. Perhaps a relatively ‘mild’ strain
of T. pallidum (like one of the non-luetic treponemes) could be isolated
and used as a live vaccine for syphilis seeking to protect against the
more virulent strains. As noted before, there is a “relative absence of
venereal syphilis in areas with a high prevalence of yaws” [23,24].

Vaccines and the two forms of immunity
The focus of a vaccine for syphilis has evolved over the past decade
or so. Initially, it has been eliciting a protective humoral response
(opsonic antibodies) in order to eliminate T. pallidum via phagocytosis.
For example, in 2006 Cullen and Cameron discussed various T.
pallidum vaccines whole cell, subunit, and non-protein carbohydrate
antigens, which might mediate ‘opsonophagocytosis’ [40].
A seminal paper in 2011 by Carlson et al. viewed the clinical course
of syphilis as being determined by the balance between delayed type
hypersensitivity (DTH) and humoral immunity to T. pallidum. The
authors argued that a strong DTH clears organisms initially from
the body, while a strong humoral response later leads to “prolonged
infection and progression to tertiary disease” [55]. They concluded
that a potential vaccine for syphilis should be directed towards the
developing the DTH response. This could be enhanced by including
BCG in the vaccine.
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Finally, in 2014, Cameron and Lukehart emphasized that a
successful vaccine should involve both the DTH response and opsonic
antibodies/phagocytosis [56]. Thus currently, there seems no consensus
for making an effective vaccine.

Summary
The theoretical threat of a multi-resistant strain of T. pallidum
appearing in the near future is compounded by the current absence of
new antibiotics effective against this putative new pathogenic strain.
Indeed, this therapeutic void prompted a recent article entitled as
a question “A return to the pre-antimicrobial era?” [57]. These two
linked concerns provided an excuse to review here new information
about syphilis (e.g., treponemal antigens, serotyping, etc.) and old
relevant studies (e.g., P. Ricord’s ‘vaccinations’, antigenic competition).
Syphilis therapeutics for over a century has been wedded to the
concept of a ‘magic bullet’ (magische Kugel) which kills infecting
spirochetes. Modification of some past ‘cure’ might include, for
example, improvement in heavy metal therapy. Fever therapy was
effective in relieving the signs and symptoms in some persons with
neurosyphilis. A review of pre-antibiotic anti-syphilitic treatments has
been submitted elsewhere. But the other important defense against
most infections is the host’s immune response. Developing a vaccine
for syphilis will build on the new information about the biology of
T. pallidum strains and their immunology. Special consideration
must be given to the two competing modalities of immunity humoral
(opsonization) and cellular (DTH).

the later 1490s, morbus gallicus involved “two disease existing sideby side” – the mild endemic syphilis (ES from Africa) long present
in Europe and a yaws strain newly introduced from America which
evoked an acute illness in the Europeans [28]. For several decades, the
severe Columbian (Y) strain dominated as virulent syphilis (VS), but
later the milder African strain (ES) became the prevalent one.
2. Philippe Ricord was born in Baltimore of parents who fled there
from the French Revolution. During his professional career in Paris,
Ricord become the leading physician treating venereal diseases. He is
most famous for establishing that syphilis and gonorrhea are distinct
diseases thus correcting the confusion in this subject created by John
Hunter’s flawed self-inoculation experiments.
References
1. McCarthy M (2014) Syphilis rate rises in the US. BMJ 349: g7756. [Crossref]
2. Denning DW, Bromley MJ (2015) Infectious Disease. How to bolster the antifungal
pipeline. Science 347: 1414-1416. [Crossref]
3. Parran T (1937) Shadow on the Land -- Syphilis. New York: Reynal & Hitchcock: 309.
4. Kent ME, Romanelli F (2008) Reexamining syphilis: an update on epidemiology,
clinical manifestations, and management. Ann Pharmacother 42: 226-236. [Crossref]
5. Katz KA, Pillay A, Ahrens K, Kohn RP, Hermanstyne K, et al. (2010) Molecular
epidemiology of syphilis--San Francisco, 2004-2007. Sex Transm Dis 37: 660-663.
[Crossref]
6. Khamsi R (2007) Syphilis rates skyrocket in China. Newscientist Health: 1-2.
7. Hvistendahl M (2012) China. An explosive return of the ‘great pox’. Science 335: 390.
[Crossref]

Acknowledgements

8. Gao J, Xu J, Sheng Y, Zhang X, Zhang C, et al. (2013) Increasing trend of syphilis
and infection resistance: a retrospective study. Int J Infect Dis 17: e971-976. [Crossref]

I gratefully acknowledge the invaluable assistance of Mrs. Amanda
Williams of the Medical Center Library of the University of Kentucky.
I am indebted for the continued support of I.S. Tray II.

9. Zhou P, Li K, Lu H, Qian Y, Gu X, et al. (2010) Azithromycin treatment failure among
primary and secondary syphilis patients in Shanghai. Sex Transm Dis 37: 726-729.
[Crossref]

Endnotes

10. Tichonova L, Borisenko K, Ward H, Meheus A, Gromyko A, et al. (1997) Epidemics
of syphilis in the Russian Federation: trends, origins, and priorities for control. Lancet
350: 210-213. [Crossref]

1. Theories on the Origin of Various Treponemal Types
E.H. Hudson (1961) postulated that the treponemal group arose
in Africa from spirochetes growing on decaying vegetable matter [26].
In the beginning, a strain appeared which thrived on the exposed
skin of natives, producing the clinical picture of yaws (Y). Around
100,000 years ago their infected descendants migrated to other parts
of the world (including the Americas), where a new strain, pinta (P),
emerged. In the warm areas of the Middle East, bejel (B) evolved and
later spread north. In dry, often cold Europe, where clothing was worn,
the spirochete could only survive and spread via the moist genital
organs, producing a mild infection called endemic syphilis (ES).
Hudson did not explain how virulent venereal syphilis (VS) appeared
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